Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oric604
- Development stage
- Preclinical
- Lead developer
- OriCell Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
OriC604 (also referred to as Ori-C604 or ORIC604) is a preclinical-stage chimeric antigen receptor T cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA). It was initially developed by OriCell Therapeutics. The drug is designed as a BCMA inhibitor for the potential treatment of diseases such as multiple myeloma and other BCMA-expressing hematologic malignancies. As of now, its highest global R&D status is preclinical[1][2].
- Other names
- ori-c604ori-c-604ori-c 604oriC604oriC-604oriC 604
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on oric604.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oric604.